Investor Presentation H1 2023

7 Investor presentation First six months of 2023 Novo NordiskⓇ International Operations diabetes care sales growth is driven by GLP-1 performance Reported Diabetes care sales and growth per IO geography GLP-1 patients and value market share in IO DKK billion Insulin I GLP-1 Growth at CER Number of patients (millions) Value market share Class growth ~45% 20% 40 6 75% 67.0% 5 60% 50 30 62% 21% Geographical regions 4 44.6% 45% I 20 20 3 30.0% 30% 55% 27% 2 -2% 11% 10 58% 1 97% -1% -11% 9% 0 0 IO EMEA China ROW May-21 May-22 GLP-1 patients -OzempicⓇ Ⓡ Rybelsus -dulaglutide IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of World; CER: Constant exchange rates Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP-1 class growth calculated as Mar'23-May 23 vs Mar'22-May 22 (Rolling 3-month average) Source: IQVIA MAT, May 2023 (Spot rate). Volume packs are converted into full-year patients based on WHO assumptions for average daily doses 11.6% 15% 10.8% 0% May-23 -VictozaⓇ -NN GLP-1

View entire presentation